Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.70 |
| ▸ | DRD2 | P14416 | 7/20 | 0.70 |
| ▸ | DRD4 | P21917 | 3/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178305 | 0.87 | DRD2 (0.70) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL13533046 | 0.86 | HTR1A (0.83) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL14367743 | 0.84 | HTR1A (0.52) | HTR1ADRD2DRD4HTR2BDRD3 | |
| Adoprazine SCHEMBL29522743 | 0.82 | DRD2 (1.00) | HTR1ADRD2DRD4HTR2BDRD3 | |
| Adoprazine SCHEMBL678503 | 0.82 | DRD2 (1.00) | HTR1ADRD2DRD4HTR2BDRD3 | |
| Adoprazine SCHEMBL4179481 | 0.82 | DRD2 (1.00) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL13533042 | 0.78 | HTR1A (0.68) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL13533020 | 0.77 | HTR1A (1.00) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL13533033 | 0.77 | HTR1A (0.67) | HTR1ADRD2DRD4HTR2BDRD3 | |
| SCHEMBL11890170 | 0.74 | HTR1A (0.69) | HTR1ADRD2DRD4HTR2BDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | claimed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | claimed |
| EP-2024363-B1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2012-08-01 | — | — | EP | claimed |
| EP-2024363-A1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | Solvay Pharmaceuticals B.V. (NL) | 2009-02-18 | — | — | EP | claimed |
| US-20070275977-A1 | N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-29 | — | — | US | claimed |
| WO-2007128694-A1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-15 | — | — | WO | claimed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | disclosed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| EP-2024363-B1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2012-08-01 | — | — | EP | disclosed |
| EP-2024363-B1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2012-08-01 | — | — | EP | disclosed |
| EP-2024363-A1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | Solvay Pharmaceuticals B.V. (NL) | 2009-02-18 | — | — | EP | disclosed |
| US-20070275977-A1 | N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-29 | — | — | US | disclosed |
| US-20070275977-A1 | N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-29 | — | — | US | disclosed |
| US-20070275977-A1 | N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-29 | — | — | US | disclosed |
| WO-2007128694-A1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128694-A1 | N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | KRAS, NRAS, HRAS | HTR1A 4542/4885DRD2 4669/4885DRD4 4505/4885 |
| US-20070275977-A1 | N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES | CHRM5, HTR5A, CHRNA5 | HTR1A 41/4885DRD2 55/4885DRD4 78/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | HTR1A 4542/4885DRD2 4669/4885DRD4 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.